Pharmacogenomics of multifactorial diseases: a focus on psoriatic arthritis

This review will outline the current pharmacogenomics knowledge about psoriatic arthritis with a special attention to the perspectives and the challenges for its implementation in the clinical practice. To date, different drugs have been developed to contrast the symptoms and the progression of psor...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacogenomics 2016-06, Vol.17 (8), p.943-951
Main Authors: Cascella, Raffaella, Strafella, Claudia, Longo, Giuliana, Maccarone, Mara, Borgiani, Paola, Sangiuolo, Federica, Novelli, Giuseppe, Giardina, Emiliano
Format: Article
Language:English
Subjects:
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Arthritis
Arthritis, Psoriatic - drug therapy
Arthritis, Psoriatic - genetics
Arthritis, Psoriatic - psychology
Cell growth
Clinical medicine
Drug development
Drug dosages
Enzymes
Genes
Genomes
healthcare approach
Humans
Inflammation
Patients
Pharmacogenetics
Pharmacogenomics
Precision medicine
precision/personalized medicine
Psoriasis
Psoriatic arthritis
Quality of Life
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Tumor necrosis factor-TNF
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c359t-19ed8710966baa730ff39b1e25f2e7b748a37e7616777adf58294e8ea0d008fc3
cites cdi_FETCH-LOGICAL-c359t-19ed8710966baa730ff39b1e25f2e7b748a37e7616777adf58294e8ea0d008fc3
container_end_page 951
container_issue 8
container_start_page 943
container_title Pharmacogenomics
container_volume 17
creator Cascella, Raffaella
Strafella, Claudia
Longo, Giuliana
Maccarone, Mara
Borgiani, Paola
Sangiuolo, Federica
Novelli, Giuseppe
Giardina, Emiliano
description This review will outline the current pharmacogenomics knowledge about psoriatic arthritis with a special attention to the perspectives and the challenges for its implementation in the clinical practice. To date, different drugs have been developed to contrast the symptoms and the progression of psoriatic arthritis. However, patients have shown high variability of drug response in relation to their genetic makeup. In this context, the advances made in the knowledge and the potentialities of genome-drugs associations paved the path for the development of a precision medicine. In fact, these associations may be successfully combined with the environment information to provide new strategies able to prevent and improve the disease management as well as to enhance the patients quality of life.
doi_str_mv 10.2217/pgs.16.20
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1800128448</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2326933304</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-19ed8710966baa730ff39b1e25f2e7b748a37e7616777adf58294e8ea0d008fc3</originalsourceid><addsrcrecordid>eNpt0LtOwzAUBmALgWgpDLwAisQCQ4pvtR02VHETSDDAbLnOMXWVxMVOBt4eowADYrItf-fX0Y_QMcFzSom82L6lORFzinfQlEjOS4U53c13LmhJORETdJDSBmNKBMf7aEIlFRUn1RQ9PK9NbI0Nb9CF1ttUBFe0Q9N7Z2wfojdNUfsEJkG6LEzhgh2y6Ypt-vrsvS1M7NfR9z4doj1nmgRH3-cMvd5cvyzvysen2_vl1WNp2aLqS1JBrSTBlRArYyTDzrFqRYAuHAW5klwZJkEKIqSUpnYLRSsOCgyuMVbOshk6G3O3MbwPkHrd-mShaUwHYUiaKIwJVZyrTE__0E0YYpe305TlDhhjmGd1PiobQ0oRnN5G35r4oQnWXw3r3LAmQlOc7cl34rBqof6VP5VmsBiBG_ohQrIeOgt6fOUJb30H_wR_AuGziNI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2326933304</pqid></control><display><type>article</type><title>Pharmacogenomics of multifactorial diseases: a focus on psoriatic arthritis</title><source>PubMed Central</source><creator>Cascella, Raffaella ; Strafella, Claudia ; Longo, Giuliana ; Maccarone, Mara ; Borgiani, Paola ; Sangiuolo, Federica ; Novelli, Giuseppe ; Giardina, Emiliano</creator><creatorcontrib>Cascella, Raffaella ; Strafella, Claudia ; Longo, Giuliana ; Maccarone, Mara ; Borgiani, Paola ; Sangiuolo, Federica ; Novelli, Giuseppe ; Giardina, Emiliano</creatorcontrib><description>This review will outline the current pharmacogenomics knowledge about psoriatic arthritis with a special attention to the perspectives and the challenges for its implementation in the clinical practice. To date, different drugs have been developed to contrast the symptoms and the progression of psoriatic arthritis. However, patients have shown high variability of drug response in relation to their genetic makeup. In this context, the advances made in the knowledge and the potentialities of genome-drugs associations paved the path for the development of a precision medicine. In fact, these associations may be successfully combined with the environment information to provide new strategies able to prevent and improve the disease management as well as to enhance the patients quality of life.</description><identifier>ISSN: 1462-2416</identifier><identifier>EISSN: 1744-8042</identifier><identifier>DOI: 10.2217/pgs.16.20</identifier><identifier>PMID: 27269419</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Arthritis ; Arthritis, Psoriatic - drug therapy ; Arthritis, Psoriatic - genetics ; Arthritis, Psoriatic - psychology ; Cell growth ; Clinical medicine ; Drug development ; Drug dosages ; Enzymes ; Genes ; Genomes ; healthcare approach ; Humans ; Inflammation ; Patients ; Pharmacogenetics ; Pharmacogenomics ; Precision medicine ; precision/personalized medicine ; Psoriasis ; Psoriatic arthritis ; Quality of Life ; Tumor Necrosis Factor-alpha - antagonists &amp; inhibitors ; Tumor necrosis factor-TNF</subject><ispartof>Pharmacogenomics, 2016-06, Vol.17 (8), p.943-951</ispartof><rights>Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd Jun 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c359t-19ed8710966baa730ff39b1e25f2e7b748a37e7616777adf58294e8ea0d008fc3</citedby><cites>FETCH-LOGICAL-c359t-19ed8710966baa730ff39b1e25f2e7b748a37e7616777adf58294e8ea0d008fc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27269419$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cascella, Raffaella</creatorcontrib><creatorcontrib>Strafella, Claudia</creatorcontrib><creatorcontrib>Longo, Giuliana</creatorcontrib><creatorcontrib>Maccarone, Mara</creatorcontrib><creatorcontrib>Borgiani, Paola</creatorcontrib><creatorcontrib>Sangiuolo, Federica</creatorcontrib><creatorcontrib>Novelli, Giuseppe</creatorcontrib><creatorcontrib>Giardina, Emiliano</creatorcontrib><title>Pharmacogenomics of multifactorial diseases: a focus on psoriatic arthritis</title><title>Pharmacogenomics</title><addtitle>Pharmacogenomics</addtitle><description>This review will outline the current pharmacogenomics knowledge about psoriatic arthritis with a special attention to the perspectives and the challenges for its implementation in the clinical practice. To date, different drugs have been developed to contrast the symptoms and the progression of psoriatic arthritis. However, patients have shown high variability of drug response in relation to their genetic makeup. In this context, the advances made in the knowledge and the potentialities of genome-drugs associations paved the path for the development of a precision medicine. In fact, these associations may be successfully combined with the environment information to provide new strategies able to prevent and improve the disease management as well as to enhance the patients quality of life.</description><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Arthritis</subject><subject>Arthritis, Psoriatic - drug therapy</subject><subject>Arthritis, Psoriatic - genetics</subject><subject>Arthritis, Psoriatic - psychology</subject><subject>Cell growth</subject><subject>Clinical medicine</subject><subject>Drug development</subject><subject>Drug dosages</subject><subject>Enzymes</subject><subject>Genes</subject><subject>Genomes</subject><subject>healthcare approach</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Patients</subject><subject>Pharmacogenetics</subject><subject>Pharmacogenomics</subject><subject>Precision medicine</subject><subject>precision/personalized medicine</subject><subject>Psoriasis</subject><subject>Psoriatic arthritis</subject><subject>Quality of Life</subject><subject>Tumor Necrosis Factor-alpha - antagonists &amp; inhibitors</subject><subject>Tumor necrosis factor-TNF</subject><issn>1462-2416</issn><issn>1744-8042</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNpt0LtOwzAUBmALgWgpDLwAisQCQ4pvtR02VHETSDDAbLnOMXWVxMVOBt4eowADYrItf-fX0Y_QMcFzSom82L6lORFzinfQlEjOS4U53c13LmhJORETdJDSBmNKBMf7aEIlFRUn1RQ9PK9NbI0Nb9CF1ttUBFe0Q9N7Z2wfojdNUfsEJkG6LEzhgh2y6Ypt-vrsvS1M7NfR9z4doj1nmgRH3-cMvd5cvyzvysen2_vl1WNp2aLqS1JBrSTBlRArYyTDzrFqRYAuHAW5klwZJkEKIqSUpnYLRSsOCgyuMVbOshk6G3O3MbwPkHrd-mShaUwHYUiaKIwJVZyrTE__0E0YYpe305TlDhhjmGd1PiobQ0oRnN5G35r4oQnWXw3r3LAmQlOc7cl34rBqof6VP5VmsBiBG_ohQrIeOgt6fOUJb30H_wR_AuGziNI</recordid><startdate>20160601</startdate><enddate>20160601</enddate><creator>Cascella, Raffaella</creator><creator>Strafella, Claudia</creator><creator>Longo, Giuliana</creator><creator>Maccarone, Mara</creator><creator>Borgiani, Paola</creator><creator>Sangiuolo, Federica</creator><creator>Novelli, Giuseppe</creator><creator>Giardina, Emiliano</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20160601</creationdate><title>Pharmacogenomics of multifactorial diseases: a focus on psoriatic arthritis</title><author>Cascella, Raffaella ; Strafella, Claudia ; Longo, Giuliana ; Maccarone, Mara ; Borgiani, Paola ; Sangiuolo, Federica ; Novelli, Giuseppe ; Giardina, Emiliano</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-19ed8710966baa730ff39b1e25f2e7b748a37e7616777adf58294e8ea0d008fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Arthritis</topic><topic>Arthritis, Psoriatic - drug therapy</topic><topic>Arthritis, Psoriatic - genetics</topic><topic>Arthritis, Psoriatic - psychology</topic><topic>Cell growth</topic><topic>Clinical medicine</topic><topic>Drug development</topic><topic>Drug dosages</topic><topic>Enzymes</topic><topic>Genes</topic><topic>Genomes</topic><topic>healthcare approach</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Patients</topic><topic>Pharmacogenetics</topic><topic>Pharmacogenomics</topic><topic>Precision medicine</topic><topic>precision/personalized medicine</topic><topic>Psoriasis</topic><topic>Psoriatic arthritis</topic><topic>Quality of Life</topic><topic>Tumor Necrosis Factor-alpha - antagonists &amp; inhibitors</topic><topic>Tumor necrosis factor-TNF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cascella, Raffaella</creatorcontrib><creatorcontrib>Strafella, Claudia</creatorcontrib><creatorcontrib>Longo, Giuliana</creatorcontrib><creatorcontrib>Maccarone, Mara</creatorcontrib><creatorcontrib>Borgiani, Paola</creatorcontrib><creatorcontrib>Sangiuolo, Federica</creatorcontrib><creatorcontrib>Novelli, Giuseppe</creatorcontrib><creatorcontrib>Giardina, Emiliano</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>UK &amp; Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacogenomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cascella, Raffaella</au><au>Strafella, Claudia</au><au>Longo, Giuliana</au><au>Maccarone, Mara</au><au>Borgiani, Paola</au><au>Sangiuolo, Federica</au><au>Novelli, Giuseppe</au><au>Giardina, Emiliano</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacogenomics of multifactorial diseases: a focus on psoriatic arthritis</atitle><jtitle>Pharmacogenomics</jtitle><addtitle>Pharmacogenomics</addtitle><date>2016-06-01</date><risdate>2016</risdate><volume>17</volume><issue>8</issue><spage>943</spage><epage>951</epage><pages>943-951</pages><issn>1462-2416</issn><eissn>1744-8042</eissn><abstract>This review will outline the current pharmacogenomics knowledge about psoriatic arthritis with a special attention to the perspectives and the challenges for its implementation in the clinical practice. To date, different drugs have been developed to contrast the symptoms and the progression of psoriatic arthritis. However, patients have shown high variability of drug response in relation to their genetic makeup. In this context, the advances made in the knowledge and the potentialities of genome-drugs associations paved the path for the development of a precision medicine. In fact, these associations may be successfully combined with the environment information to provide new strategies able to prevent and improve the disease management as well as to enhance the patients quality of life.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>27269419</pmid><doi>10.2217/pgs.16.20</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1462-2416
ispartof Pharmacogenomics, 2016-06, Vol.17 (8), p.943-951
issn 1462-2416
1744-8042
language eng
recordid cdi_proquest_miscellaneous_1800128448
source PubMed Central
subjects Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Arthritis
Arthritis, Psoriatic - drug therapy
Arthritis, Psoriatic - genetics
Arthritis, Psoriatic - psychology
Cell growth
Clinical medicine
Drug development
Drug dosages
Enzymes
Genes
Genomes
healthcare approach
Humans
Inflammation
Patients
Pharmacogenetics
Pharmacogenomics
Precision medicine
precision/personalized medicine
Psoriasis
Psoriatic arthritis
Quality of Life
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Tumor necrosis factor-TNF
title Pharmacogenomics of multifactorial diseases: a focus on psoriatic arthritis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T09%3A21%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacogenomics%20of%20multifactorial%20diseases:%20a%20focus%20on%20psoriatic%20arthritis&rft.jtitle=Pharmacogenomics&rft.au=Cascella,%20Raffaella&rft.date=2016-06-01&rft.volume=17&rft.issue=8&rft.spage=943&rft.epage=951&rft.pages=943-951&rft.issn=1462-2416&rft.eissn=1744-8042&rft_id=info:doi/10.2217/pgs.16.20&rft_dat=%3Cproquest_cross%3E2326933304%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c359t-19ed8710966baa730ff39b1e25f2e7b748a37e7616777adf58294e8ea0d008fc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2326933304&rft_id=info:pmid/27269419&rfr_iscdi=true